Healthcare
Omnicell, Inc.(OMCL)
Live Price
Offline$39.05
+1.43% today
1Y Change
+38.83%
Window
Jun 25, 2025 โ Jun 16, 2026
- Market Cap
- $1.95B
- Revenue Growth
- +6.5%
- EPS Growth
- -83.5%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 25, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Omnicell, Inc. (OMCL) is a Healthcare stock with a market cap of $1.95B and listed on NASDAQ. The stock last traded around $39.05 and up 38.8% across the available one-year price window (Jun 25, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of +6.5%, EPS growth of -83.5%, a dividend yield of 0.0%. What stands out right now is revenue +6.5%, EPS -83.5%, free cash flow -42.6% with operating margin 2.8% and ROIC 1.2%. Valuation already assumes a fairly strong business story at P/E 94.9 and price/sales 1.6. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines OMCL price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+6.5% vs +7.6% peer median
Operating Margin
Below sector median
+2.8% vs +19.4% peer median
P/E
Above sector median
94.9 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 5, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +6.5% and EPS is at -83.5%, with operating margin around 2.8%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -0.2% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 5, 2026 | โ | +0.5% | +0.3% | -3.8% |
2026 Feb 5, 2026 | -14.9% | -5.1% | -7.4% | +5.7% |
2025 Oct 30, 2025 | +41.7% | -0.0% | +6.5% | +8.7% |
Benchmark Edge
OMCL vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
OMCL
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
OMCL Max Drawdown
-37.05%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for OMCL and SPY.
Company Overview
Omnicell, Inc.
NASDAQ Global Select
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.
- Leadership
- Randall A. Lipps
- IPO Date
- Aug 9, 2001
- Employees
- 3.6k
- Street Address
- 590 East Middlefield Road
- Mailing
- Mountain View, CA, 94043
- Region
- Mountain View, CA, US
- Reporting Currency
- USD
- Investor Line
- 650 251 6100
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 94.9
- EV/EBITDA
- 14.7
- Price/Sales
- 1.6
- Price/Book
- 1.5
Growth
- Revenue
- +6.5%
- EPS
- -83.5%
- Free Cash Flow
- -42.6%
Profitability
- Gross Margin
- 43.5%
- Operating Margin
- 2.8%
- Net Margin
- 1.7%
- ROE
- 1.6%
- ROIC
- 1.2%
Balance Sheet
- Debt/Equity
- 0.02
- Current Ratio
- 1.50
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.